| Information On The Segment And Reconciliation To Net Loss |
As of December 31, 2025 and 2024, the Company did not have any significant long-lived assets located outside of the United States. Information on the segment and reconciliation to net loss is as follows (in thousands): | | | | | | | | | | | | | Year Ended December 31, | | 2025 | | 2024 | | Revenue under licensing agreements | $ | — | | | $ | 925 | | | | | | | Program specific expenses: | | | | | Rett syndrome | 25,841 | | | 12,104 | | | Batten disease | 1,513 | | | 5,869 | | | Early Discovery | 3,223 | | | 5,401 | | | Unallocated internal expenses: | | | | | Personnel-related | 21,493 | | | 18,476 | | Stock-based compensation | 6,472 | | | 4,506 | | | Manufacturing | 13,018 | | | 12,098 | | Other (a) | 3,451 | | | 2,463 | | Total research and development expenses | $ | 75,011 | | | $ | 60,917 | | | | | | | General and administrative specific expenses: | | | | | Personnel-related | $ | 9,257 | | | $ | 8,098 | | Stock-based compensation | 7,711 | | | 3,813 | | | Professional and consultant fees | 4,586 | | | 4,558 | | | Office-related | 2,465 | | | 2,534 | | Other (b) | 4,298 | | | 3,610 | | | Total general and administrative expenses | $ | 28,317 | | | $ | 22,613 | | | | | | Other income (c) | 12,977 | | | 7,461 | | | Net loss | $ | (90,351) | | | $ | (75,144) | | (a) The Other expense segment items category within research and development expense is mainly comprised of: Consultant fees for programs not specified above, IT Software and network support and rent expenses. (b) The Other expense segment items category within general and administrative expense is mainly comprised of: Insurance, IT software and network support, market research, and tax expenses. (c) Other income (expense) included in net loss includes interest income, interest expense, other income and other expense. |
|